axicabtagene ciloleucel
AXP000014.1 · CAR-T cell therapy
- Platform
- autologous CAR-T
- Targets
- CD19
- Originator
- National Cancer Institute
- Sponsor
- Kite Pharma (Gilead Sciences)
Names
| Name | Type | Source |
|---|---|---|
| axicabtagene ciloleucel | preferred name, INN | curator, ncit |
| Yescarta | brand | ncit |
| KTE-C19 | code | ncit |
| axi-cel | synonym | ncit |
Virus
- Role
- Ex vivo gene transfer
- Family
- Retroviridae
- Virus
- retrovirus
- Replication
- non replicating
- Modifications
- replication-incompetent retroviral vector; murine anti-CD19 scFv with CD28 and CD3 zeta domains. The label does not name the retrovirus, so `virus` says only retrovirus
- Transgenes
- anti-CD19 chimeric antigen receptor
- Route
- ex vivo, intravenous
- Carrier
- autologous T cells
- Source
- evidence
Cross-references
- NCI Thesaurus
- C120309
- Wikidata
- Q30314851
- FDA UNII
- U2I8T43Y7R
Approvals
| Agency | Region | Date | Status | Brand | Indication | Source |
|---|---|---|---|---|---|---|
| FDA | US | 2017-10-18 | approved | Yescarta | Adults with large B-cell lymphoma refractory to or relapsing within 12 months of first-line chemoimmunotherapy; after two or more lines; and relapsed or refractory follicular lymphoma after two or more lines (accelerated approval). Not for primary CNS lymphoma | source |
| EMA | EU | 2018-08-23 | approved | Yescarta | Adults with diffuse large B-cell lymphoma or high-grade B-cell lymphoma refractory to or relapsing within 12 months of first-line chemoimmunotherapy; relapsed or refractory DLBCL or primary mediastinal large B-cell lymphoma after two or more lines; relapsed or refractory follicular lymphoma after three or more lines | source |
| PMDA | JP | 2021-01-22 | approved | Yescarta | Relapsed or refractory large B-cell lymphoma: diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, transformed follicular lymphoma and high-grade B-cell lymphoma | source |
Clinical trials (58)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06902012 | Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma | Recruiting | Phase 1/2 | 2027-02 | 2028-02 | 15 | Relapsed/Refractory Diffuse Large B-cell Lymphoma |
| NCT07892027 | Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy | Recruiting | Phase 2 | 2026-11-01 | 2028-05-01 | 26 | Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Mantle Cell Lymphoma |
| NCT07932730 | Disulfiram for Preventing Treatment Complications in Patients Undergoing CAR T-cell Therapy for Relapsed or Refractory Diffuse Large B-cell Lymphoma | Not yet recruiting | Phase 1/2 | 2026-11 | 2028-05 | 12 | Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma |
| NCT07725406 | Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma | Recruiting | Phase 1 | 2026-11 | 2028-08-01 | 32 | Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed or Refractory Multiple Myeloma (MM) |
| NCT07763210 | Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma | Recruiting | Phase 2 | 2026-09-25 | 2028-03-01 | 59 | Non-hodgkin Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma; Refractory Marginal Zone Lymphoma |
| NCT07606937 | A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma. | Recruiting | Early phase 1 | 2026-06-12 | 2026-11-30 | 12 | Relapsed/Refractory Large B-cell Lymphoma |
| NCT07479797 | Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy | Active not recruiting | Phase 3 | 2026-05-22 | 2031-05 | 550 | Relapsed or Refractory Large B-cell Lymphoma |
| NCT07538635 | CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors. | Recruiting | Phase 2 | 2026-04-20 | 2028-02-29 | 20 | High-risk R/R LBCL |
| NCT07052305 | NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma | Recruiting | Phase 1 | 2026-03-12 | 2027-11-30 | 24 | Large B-cell Lymphoma |
| NCT07326371 | Glofitamab Combined With CAR-T Therapy in R/R DLBCL | Not yet recruiting | Phase 2 | 2026-03 | 2027-07 | 24 | DLBCL - Diffuse Large B Cell Lymphoma |
| NCT07042438 | Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells | Recruiting | Phase 2 | 2026-02-11 | 2029-01-23 | 56 | Recurrent Diffuse Large B-Cell Lymphoma; Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma |
| NCT07188558 | A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy | Recruiting | Phase 3 | 2026-01-12 | 2029-12 | 400 | Diffuse Large B Cell Lymphoma (DLBCL); Diffuse Large B Cell Lymphoma Refractory; Diffuse Large B Cell Lymphoma Relapsed; Large B-cell Lymphoma; Lymphoma, B-Cell; Non-Hodgkin Lymphoma; Non-Hodgkin Lymphoma Refractory/ Relapsed; Refractory Non-Hodgkin Lymphoma; Relapsed Non-Hodgkin Lymphoma |
| NCT06935136 | Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma | Not yet recruiting | 2025-04-30 | 2026-10-09 | 60 | CAR-T Cell Therapy; High-risk Large B-cell Lymphoma (LBCL) | |
| NCT06912529 | Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma | Terminated | Phase 2 | 2025-03-13 | 2025-07-25 | 1 | B-cell Lymphoma Recurrent; B-cell Lymphoma Refractory |
| NCT05077527 | Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma | Recruiting | Phase 1 | 2025-02-13 | 2028-01-31 | 20 | AIDS-Related Diffuse Large B-cell Lymphoma; AIDS-Related Non-Hodgkin Lymphoma; HIV Infection; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Grade 3b Follicular Lymphoma; Recurrent High Grade B-Cell Lymphoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Recurrent Transformed B-Cell Non-Hodgkin Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Grade 3b Follicular Lymphoma; Refractory High Grade B-Cell Lymphoma; Refractory Non-Hodgkin Lymphoma; Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Refractory Transformed B-Cell Non-Hodgkin Lymphoma |
| NCT06826118 | Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma | Recruiting | Phase 2 | 2025-02-08 | 2026-12-31 | 30 | Follicular Lymphoma; Lymphoma; Refractory Lymphoma |
| NCT07254754 | Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma | Recruiting | Phase 2 | 2024-11-20 | 2027-01-31 | 45 | DIFFUSE LARGE B-CELL LYMPHOMA |
| NCT06609304 | Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma | Recruiting | Phase 4 | 2024-09-30 | 2026-08-31 | 20 | Lymphoma, B-Cell |
| NCT06550141 | Emapalumab Prevention of CAR-T Cell Associated Toxicities | Recruiting | Phase 2 | 2024-09-18 | 2027-08-01 | 28 | Diffuse Large B Cell Lymphoma; Follicular Lymphoma; High-grade B-cell Lymphoma; Large B-cell Lymphoma; Primary Mediastinal Large B-cell Lymphoma; Refractory Non-Hodgkin Lymphoma; Relapsed Non-Hodgkin Lymphoma |
| NCT06213311 | A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma | Recruiting | Phase 2 | 2024-05-07 | 2027-07-31 | 40 | B Cell Lymphoma |
| NCT06218602 | Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy. | Recruiting | Phase 2 | 2024-02-19 | 2028-08-01 | 40 | Lymphoma |
| NCT06043323 | A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma | Recruiting | Phase 2 | 2024-01-08 | 2028-09-01 | 20 | Follicular Lymphoma |
| NCT06104592 | Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL | Recruiting | Phase 2 | 2023-11-08 | 2026-12 | 27 | Large B-cell Lymphoma; Relapsed Non-Hodgkin Lymphoma |
| NCT05950802 | Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta | Recruiting | Phase 1 | 2023-07-14 | 2027-09 | 40 | DLBCL - Diffuse Large B Cell Lymphoma |
| NCT05633615 | Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Recruiting | Phase 2 | 2023-06-12 | 2030-06-30 | 396 | Diffuse Large B-Cell Lymphoma; Grade 3b Follicular Lymphoma; Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Transformed Follic Lymph to Diff Large B-Cell Lymphoma; Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma |
| NCT05794958 | Axicabtagene Ciloleucel Reinfusion(Axi-Cel-2) in Relapsed/Refractory 2nd Line High-Risk NHL | Active not recruiting | Phase 1 | 2023-05-23 | 2026-04-13 | 27 | Large B-cell Lymphoma; Non-Hodgkin Lymphoma |
| NCT05757219 | Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy | Recruiting | Phase 2 | 2023-05-19 | 2027-02 | 27 | Diffuse Large B Cell Lymphoma |
| NCT05800067 | Axi-cel Retreatment in Relapsed/Refractory LBCL | Unknown | 2023-03-04 | 2024-12-31 | 32 | CAR-T Retreatment | |
| NCT05605899 | Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma | Active not recruiting | Phase 3 | 2023-02-10 | 2031-03 | 300 | High-risk Large B-cell Lymphoma (LBCL) |
| NCT05641428 | Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL | Active not recruiting | Phase 2 | 2022-10-18 | 2027-06 | 340 | DLBCL - Diffuse Large B Cell Lymphoma; NHL |
| NCT05371093 | Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma | Active not recruiting | Phase 3 | 2022-09-22 | 2030-10 | 231 | Relapsed/Refractory Follicular Lymphoma |
| NCT05459571 | Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma | Completed | Phase 2 | 2022-08-09 | 2025-11-24 | 35 | Relapsed or Refractory Large B-cell Lymphoma |
| NCT05370547 | Chidamide Bridging for CAR-T Therapy | Unknown | Phase 1/2 | 2022-05-25 | 2024-06-30 | 120 | Non Hodgkin's Lymphoma |
| NCT05041309 | Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies | Enrolling by invitation | 2021-12-15 | 2040-12 | 1500 | Autoimmune Diseases; Solid and Hematological Malignancies | |
| NCT05108805 | Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting | Completed | Phase 4 | 2021-12-02 | 2023-12-08 | 25 | Diffuse Large B-cell Lymphoma; Large B-cell Lymphoma |
| NCT05075603 | Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy | Completed | Phase 1 | 2021-07-29 | 2024-12-18 | 17 | DLBCL Arising From Follicular Lymphoma; High-grade B-cell Lymphoma; Primary Mediastinal Large B-cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-cell Lymphoma |
| NCT04855253 | Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL | Suspended | Phase 1/2 | 2021-06-09 | 2027-09 | 30 | DLBCL; DLBCL Arising From Follicular Lymphoma; Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma |
| NCT04531046 | Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation | Active not recruiting | Phase 2 | 2021-03-10 | 2022-04-19 | 62 | B-Cell Lymphoma Refractory; B-cell Lymphoma Recurrent |
| NCT05349201 | CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI) | Completed | 2020-12-09 | 2021-05-28 | 273 | Acute Lymphoblastic Leukemia (ALL); Diffuse Large B-Cell Lymphoma (DLBCL) | |
| NCT04608487 | Axi-cel in CNS Lymphoma | Active not recruiting | Phase 1 | 2020-12-04 | 2025-06-14 | 18 | Lymphoma; Lymphoma Cns |
| NCT04257578 | Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma | Active not recruiting | Phase 1/2 | 2020-12-02 | 2025-08-07 | 23 | B-Cell Non-Hodgkin Lymphoma; Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma; High Grade B-Cell Lymphoma; Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma |
| NCT04150913 | A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity | Completed | Phase 2 | 2020-10-01 | 2023-10-30 | 15 | Cytokine Release Syndrome; Neurotoxicity; Neurotoxicity Syndromes; Non Hodgkin Lymphoma; Refractory Non-Hodgkin Lymphoma; Relapsed Non Hodgkin Lymphoma |
| NCT04432506 | Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma | Completed | Phase 2 | 2020-07-27 | 2024-05-28 | 22 | Hematopoietic and Lymphoid Cell Neoplasm; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent High Grade B-Cell Lymphoma; Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory High Grade B-Cell Lymphoma; Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma |
| NCT04314843 | Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma | Terminated | Phase 1 | 2020-05-26 | 2021-03-16 | 6 | Relapsed/Refractory Large B-cell Lymphoma |
| NCT04319237 | Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes | Completed | 2020-03-10 | 2023-07-14 | 60 | Diffuse Large B Cell Lymphoma; Transformed Lymphoma | |
| NCT04205838 | Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma | Terminated | Phase 2 | 2020-03-04 | 2026-02-19 | 23 | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; High Grade B-Cell Lymphoma; Progressive Disease; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent High Grade B-Cell Lymphoma; Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory High Grade B-Cell Lymphoma; Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma |
| NCT04071366 | A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy | Completed | Phase 2 | 2020-02-07 | 2023-02-23 | 112 | Cytokine Release Syndrome |
| NCT04002401 | Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma | Completed | Phase 2 | 2019-11-05 | 2023-01-30 | 27 | Refractory Large B-cell Lymphoma |
| NCT03761056 | Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma | Completed | Phase 2 | 2019-01-29 | 2023-10-12 | 42 | B-cell Lymphoma |
| NCT03642626 | MT2017-45: CAR-T Cell Therapy for Heme Malignancies | Active not recruiting | Phase 2 | 2018-12-18 | 2024-02-09 | 150 | Acute Lymphoblastic Leukemia; Large B-cell Lymphoma |
| NCT03704298 | Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma | Terminated | Phase 1 | 2018-11-20 | 2021-05-07 | 15 | Relapsed/Refractory Large B-cell Lymphoma |
| NCT03391466 | Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma | Completed | Phase 3 | 2018-01-25 | 2021-03-18 | 359 | Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) |
| NCT03105336 | A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma | Completed | Phase 2 | 2017-06-06 | 2024-12-20 | 159 | Follicular Lymphoma; Indolent Non-Hodgkin Lymphoma; Marginal Zone Lymphoma |
| NCT02926833 | Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Completed | Phase 1/2 | 2016-09-29 | 2023-01-12 | 37 | Refractory Diffuse Large B Cell Lymphoma |
| NCT02601313 | Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2) | Completed | Phase 2 | 2015-11-09 | 2023-09-22 | 105 | Relapsed/Refractory Mantle Cell Lymphoma |
| NCT02348216 | Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma | Completed | Phase 1/2 | 2015-04-21 | 2023-07-27 | 307 | High Grade B-cell Lymphoma (HGBCL); Primary Mediastinal B-cell Lymphoma (PMBCL); Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B-Cell Lymphoma; Transformed Follicular Lymphoma (TFL) |
| NCT05776160 | Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel | Available | Follicular Lymphoma; Large B-cell Lymphoma | ||||
| NCT03153462 | Axicabtagene Ciloleucel Expanded Access Study | Approved for marketing | Relapsed/Refractory Diffuse Large B Cell Lymphoma; Relapsed/Refractory High-Grade B-Cell Lymphoma; Relapsed/Refractory Primary Mediastinal B Cell Lymphoma; Relapsed/Refractory Transformed Follicular Lymphoma |
Unconfirmed matches (2)
Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions | Matched by |
|---|---|---|---|---|---|---|---|---|
| NCT06271369 | Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study. | Completed | 2022-08-11 | 2023-02-15 | 613 | Diffuse Large B-cell Lymphoma | name in title: axi-cel | |
| NCT04514029 | Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel | Active not recruiting | Early phase 1 | 2020-08-06 | 2023-11-03 | 37 | Lymphoma | name in title: axi-cel |
Recent changes
| Seen | Trial | Change | Detail | Title |
|---|---|---|---|---|
| 2026-11-12 | NCT05459571 | results posted | Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma | |
| 2026-11-12 | NCT07932730 | new trial | Disulfiram for Preventing Treatment Complications in Patients Undergoing CAR T-cell Therapy for Relapsed or Refractory Diffuse Large B-cell Lymphoma |
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41062320 | Persistent Unilateral Pleural Effusion with Chimeric Antigen Receptor T-cell Infiltration in Primary Mediastinal Large B-cell Lymphoma. | Internal medicine (Tokyo, Japan) | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41076192 | CAR-T for Management of R/R PTLD Following Lung Transplant: A Multi-center Retrospective Study. | Transplantation and cellular therapy | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41160777 | Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3. | Blood | 2026 | cited by trial NCT02601313 |
| PMID 41231109 | Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2026 | name in title: axicabtagene ciloleucel |
| PMID 41437832 | Locally manufactured versus commercial CAR T therapy for large B-cell lymphoma: a multicenter propensity scorematched analysis. | Haematologica | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41492094 | Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trial. | Nature cancer | 2026 | cited by trial NCT04002401 |
| PMID 41508112 | Multicenter real-life evaluation of the Post-CAR prognostic index for patients with large B-cell lymphoma after CAR-T failure. | Journal of hematology & oncology | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41512176 | Health-related quality of life after second-line axi-cel in transplant-ineligible patients with large B-cell lymphoma. | Blood advances | 2026 | cited by trial NCT04531046 |
| PMID 41641106 | Case Report: CD19 CAR-T therapy induces durable remission in a pediatric patient with TP53-mutated, refractory Burkitt lymphoma: a 30-month follow-up. | Frontiers in oncology | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41686452 | Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma. | Blood advances | 2026 | cited by trial NCT02601313 |
| PMID 41716106 | [Efficacy of axi-cel in a patient with high-grade large B-cell lymphoma refractory to first-line therapy: importance of early identification and referral of the patient potentially eligible for CAR-T in defining the patient's outcome]. | Recenti progressi in medicina | 2026 | name in title: axi-cel |
| PMID 41716107 | [CAR-T cell immunotherapy in early relapse after introduction chemoimmunotherapy]. | Recenti progressi in medicina | 2026 | name in abstract: axi-cel |
| PMID 41716108 | [Beyond comorbidities: CAR-T as a safe and effective option in frail patients with second-line DLBCL]. | Recenti progressi in medicina | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41716109 | [Refractory DLBCL to a polatuzumab-containing regimen: efficacy of CAR-T therapy in second line with radiotherapy bridging]. | Recenti progressi in medicina | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41716111 | [CAR-T: an effective option in primary refractory patients]. | Recenti progressi in medicina | 2026 | name in abstract: axi-cel |
| PMID 41747197 | Real-world outcomes and toxicities of CAR-T in relapsed/refractory follicular lymphoma: a multicenter cohort study. | Blood advances | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41763314 | Outpatient Versus Inpatient Axicabtagene Ciloleucel CAR T-Cell Therapy in Non-Hodgkin's Lymphoma: Insights From A US Multicenter Transplant and Cellular Therapy Network. | Transplantation and cellular therapy | 2026 | name in title: axicabtagene ciloleucel |
| PMID 41765136 | Landmark-Based Evaluations of Long-Term Outcomes After CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma. | Transplantation and cellular therapy | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41777880 | Non-ICANS neurotoxicities CD19-directed CAR T-cell therapy and the emergence of movement and neurocognitive treatment-emergent adverse events: a case report. | Frontiers in immunology | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41856668 | Risk Assessment in Large B-Cell Lymphoma Using Metabolic Tumor Volume: Real-World Data from a Multicenter Cohort of Patients Undergoing CAR T-Cell Therapy. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41993175 | Case Report: Transverse myelitis following CAR-T cell therapy for post-transplant lymphoproliferative disorder. | Frontiers in immunology | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42036693 | Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2. | Journal of hematology & oncology | 2026 | cited by trial NCT02601313 |
| PMID 42134094 | Real-world outcomes of Axicabtagene Ciloleucel CAR-T therapy in large B-cell lymphoma: a single-center observational study. | Cytotherapy | 2026 | name in title: axicabtagene ciloleucel |
| PMID 42178058 | Impact of ASTCT Toxicity Grading System on Outcomes After CAR-T for Mature B-Cell Malignancies. | Transplantation and cellular therapy | 2026 | name in abstract: axi-cel |
| PMID 42285114 | Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study. | The Lancet. Haematology | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42285354 | Impact of Bridging Response on Outcomes after CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma. | Transplantation and cellular therapy | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42341321 | Late cytopenia after CD19 chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a Cell Therapy Consortium analysis. | Blood advances | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42745632 | Plain language summary of the ZUMA-5 study of axicabtagene ciloleucel for people with relapsed or refractory slow-growing non-Hodgkin lymphoma. | Future oncology (London, England) | 2026 | cited by trial NCT03105336 |
| PMID 42770797 | A patient's experience with follicular lymphoma from diagnosis to cure: the life-changing impact of CAR T-cell therapy. | Future oncology (London, England) | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42816413 | Biopsy-proven inflammatory pulmonary opacities mimicking lymphoma relapse after CD19 CAR-T-cell therapy. | Journal of clinical and experimental hematopathology : JCEH | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42877902 | Pseudoprogression after Axi-cel in Primary Refractory PMBCL following Failed Bridging: Case Report and Management Considerations. | Case reports in oncology | 2026 | name in title: axi-cel |
| PMID 42898883 | Irreversible paraplegia due to transverse myelitis as a rare complication of CAR T-cell therapy in a patient with B-cell lymphoma. | Postepy psychiatrii neurologii | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42909844 | Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel as Second-Line Treatment for Large B Cell Lymphoma in the United States. | Advances in therapy | 2026 | cited by trial NCT03391466 |
| PMID 42930590 | Baseline Tumor Transcriptional Features and Event-Free Survival After Anti-CD19 CAR T-Cell Therapy with Axicabtagene Ciloleucel in Large B-Cell Lymphoma: An Exploratory Reanalysis of the Randomized ZUMA-7 Trial. | Medical sciences (Basel, Switzerland) | 2026 | name in title: axicabtagene ciloleucel |
| PMID 39425562 | Severe cytopenia after chimeric antigen receptor-T cell driven by large granular lymphocytes and responsive to steroids. | British journal of haematology | 2025 | name in abstract: axicabtagene ciloleucel |
| PMID 39441941 | Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy. | Blood | 2025 | cited by trial NCT06218602 |
| PMID 39840879 | [Pseudoprogression after CAR-T cell therapy: friend or foe?]. | Recenti progressi in medicina | 2025 | name in abstract: axicabtagene ciloleucel |
| PMID 39840881 | [CAR-T therapy in elderly patients with relapsed/refractory diffuse large B-cell lymphoma. Clinical case of the San Martino Hospital in Genoa]. | Recenti progressi in medicina | 2025 | name in abstract: axicabtagene ciloleucel |
| PMID 39928957 | Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma. | Blood advances | 2025 | cited by trial NCT04150913 |
| PMID 39931889 | [The first Italian patient affected by diffuse large B-cell lymphoma treated with axi-cel in the second line: innovation and tradition]. | Recenti progressi in medicina | 2025 | name in title: axi-cel |
| PMID 39931890 | [Experience of therapy with axi-cel CAR-T in an elderly patient suffering from double expressor DLBCL in an advanced stage and refractory to first-line chemoimmunotherapy]. | Recenti progressi in medicina | 2025 | name in title: axi-cel |
| PMID 39931891 | [Successfully treatment with axicabtagene ciloleucel of a female patient with an early relapsed diffuse large B-cell lymphoma]. | Recenti progressi in medicina | 2025 | name in title: axicabtagene ciloleucel |
| PMID 39938007 | Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma. | Blood | 2025 | name in abstract: axicabtagene ciloleucel |
| PMID 39938019 | Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study. | Blood | 2025 | cited by trial NCT03761056 |
| PMID 39998830 | Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma. | JAMA network open | 2025 | name in abstract: axicabtagene ciloleucel |
| PMID 40025178 | Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study. | Bone marrow transplantation | 2025 | name in abstract: axicabtagene ciloleucel |
| PMID 40090005 | Itacitinib for the prevention of IEC therapy-associated CRS: results from the 2-part phase 2 INCB 39110-211 study. | Blood | 2025 | cited by trial NCT04071366 |
| PMID 40128603 | Feasibility of axicabtagene ciloleucel in the outpatient setting: primary analysis of prospective trial. | Bone marrow transplantation | 2025 | name in title: axicabtagene ciloleucel |
| PMID 40203192 | Bridging radiotherapy before chimeric antigen receptor T cells for B-cell lymphomas: an ILROG multicenter study. | Blood advances | 2025 | name in abstract: axicabtagene ciloleucel |
| PMID 40246539 | Semiquantitative PET Parameters Refine Prognosis in CAR T-Treated Lymphoma After 1 and 3 Months: A Prospective Single-Center Study. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2025 | name in abstract: axicabtagene ciloleucel |
| PMID 40347097 | Efficacy of Axicabtagene Ciloleucel Compared to Historical Treatments for Relapsed/Refractory Diffuse Large B-Cell Lymphoma of Asian Descent: A Matching Adjusted Indirect Comparison of ZUMA-1 vs REAL-TREND. | Hematological oncology | 2025 | name in title: axicabtagene ciloleucel |
| PMID 40438977 | CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE study. | Haematologica | 2025 | name in abstract: axicabtagene ciloleucel |
| PMID 40536814 | Clinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma. | The Journal of clinical investigation | 2025 | cited by trial NCT03105336 |
| PMID 40589238 | Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experience. | British journal of haematology | 2025 | name in abstract: axi-cel |
| PMID 40708270 | Matching-adjusted indirect comparison of lisocabtagene maraleucel versus axicabtagene ciloleucel for second-line treatment of patients with early relapsed or refractory large B-cell lymphoma. | Leukemia & lymphoma | 2025 | name in title: axicabtagene ciloleucel |
| PMID 40759437 | Classification of patients with relapsed/refractory large B-cell lymphoma who do not develop early CRS/NE toxicity using ZUMA clinical trial data. | Journal for immunotherapy of cancer | 2025 | name in abstract: axicabtagene ciloleucel |
| PMID 40815804 | Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma. | Blood advances | 2025 | name in abstract: axicabtagene ciloleucel |
| PMID 40902085 | An AI model classifies risks of early relapse post-CAR T-cell therapy in a multicenter real-world population with DLBCL. | Blood advances | 2025 | name in abstract: axicabtagene ciloleucel |
| PMID 40948517 | Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysis. | American journal of cancer research | 2025 | cited by trial NCT05459571 |
| PMID 40954138 | Use of Dasatinib for the Treatment of Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome After Axicabtagene Ciloleucel Infusion: A Case Report. | European journal of haematology | 2025 | name in title: axicabtagene ciloleucel |
| PMID 41100801 | Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | cited by trial NCT03105336 |
| PMID 41126598 | The French Experience of Pharmacists and CAR T-Cells: A Study of the French Society of Oncology Pharmacy (SFPO). | Hematological oncology | 2025 | name in abstract: axi-cel |
| PMID 41170601 | Liquid biopsy-directed therapy in primary bone lymphoma: venetoclax-Pola-R-CHP and CAR-T achieve molecular remission: a case report. | Current medical research and opinion | 2025 | name in abstract: axicabtagene ciloleucel |
| PMID 41306534 | Case Report: Rare adverse events following CAR-T therapy in patients with relapsed/refractory diffuse large B-cell lymphoma. | Frontiers in oncology | 2025 | name in abstract: axicabtagene ciloleucel |
| PMID 41583270 | Cytomegalovirus Lymphadenitis After Anti-CD19 Chimeric Antigen Receptor T-cell (CAR-T): An Underappreciated Etiology of Hypermetabolic Lymphadenopathy in the Post-CAR-T Setting. | Cureus | 2025 | name in abstract: axicabtagene ciloleucel |
| PMID 37879047 | Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). | Blood | 2024 | name in title: axicabtagene ciloleucel |
| PMID 37973893 | Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy. | Bone marrow transplantation | 2024 | name in abstract: axicabtagene ciloleucel |
| PMID 38051550 | Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium. | Blood advances | 2024 | name in title: axicabtagene ciloleucel |
| PMID 38114616 | Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy. | European journal of nuclear medicine and molecular imaging | 2024 | name in abstract: axicabtagene ciloleucel |
| PMID 38196817 | Exacerbations of Persistent Neurotoxicity following Axicabtagene Ciloleucel in a Patient with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Case Report. | Case reports in oncology | 2024 | name in title: axicabtagene ciloleucel |
| PMID 38315832 | Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7. | Blood advances | 2024 | name in title: axicabtagene ciloleucel |
| PMID 38359407 | Monocytes in leukapheresis products affect the outcome of CD19-targeted CAR T-cell therapy in patients with lymphoma. | Blood advances | 2024 | name in abstract: axicabtagene ciloleucel |
| PMID 38459167 | Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study. | Leukemia | 2024 | name in title: axicabtagene ciloleucel |
| PMID 38504387 | Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy. | American journal of hematology | 2024 | name in title: axicabtagene ciloleucel |
| PMID 38552193 | Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024 | name in abstract: axicabtagene ciloleucel |
| PMID 38557775 | Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume. | Blood | 2024 | name in title: axicabtagene ciloleucel |
| PMID 38594876 | Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK. | British journal of haematology | 2024 | name in abstract: axicabtagene ciloleucel |
| PMID 38635762 | Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity. | Blood | 2024 | cited by trial NCT02348216 |
| PMID 38703571 | Rapid response in relapsed follicular lymphoma to novel anti-CD19 CAR-T therapy with pseudo-progression and cytomegalovirus infection: A case report. | International immunopharmacology | 2024 | name in abstract: Yescarta |
| PMID 38865660 | Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. | The New England journal of medicine | 2024 | name in abstract: axicabtagene ciloleucel |
| PMID 38953781 | A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas. | Blood cancer discovery | 2024 | name in title: axicabtagene ciloleucel |
| PMID 38982730 | Toxic epidermal necrolysis-like cutaneous toxicity following chimeric antigen receptor T-cell therapy in recurrent large B-cell lymphoma. | Journal of cutaneous pathology | 2024 | name in abstract: axicabtagene ciloleucel |
| PMID 39069076 | Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC/GELTAMO. | Transplantation and cellular therapy | 2024 | name in abstract: axicabtagene ciloleucel |
| PMID 39240498 | Investigating the Influence of Covariates on Axicabtagene Ciloleucel (axi-cel) Kinetics in Patients with Non-Hodgkin's Lymphoma. | Clinical pharmacokinetics | 2024 | cited by trial NCT02348216 |
| PMID 39266425 | [Real-life evaluation of the care pathway of patients eligible for axicabtagene ciloleucel treatment: Analysis of a multicenter retrospective cohort (IMPA-CT study)]. | Bulletin du cancer | 2024 | name in title: axicabtagene ciloleucel |
| PMID 39396632 | Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable/Progressive Large B Cell Lymphoma at Lymphodepletion-A Phase 2, Prospective Interventional Study. | Transplantation and cellular therapy | 2024 | name in abstract: axicabtagene ciloleucel |
| PMID 39417342 | Hemophagocytic lymphohistiocytosis in a patient with Epstein-Barr virus-positive diffuse large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy. | Immunotherapy | 2024 | name in abstract: axicabtagene ciloleucel |
| PMID 39580601 | EEG features and synek scale indicate severity of neurotoxicity in adult patients treated with CD19 CAR T-cell therapy. | Scientific reports | 2024 | name in abstract: axicabtagene ciloleucel |
| PMID 39717043 | Cytokine Release Syndrome After CAR T-Cell Therapy in a 35-Year-Old Patient With Pneumocystis jiroveci Pneumonia and Cytomegalovirus Viremia. | Case reports in medicine | 2024 | name in abstract: axicabtagene ciloleucel |
| PMID 35658525 | Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023 | cited by trial NCT02601313 |
| PMID 36399286 | A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis. | International journal of hematology | 2023 | name in title: axicabtagene ciloleucel |
| PMID 36508286 | Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome. | Blood advances | 2023 | name in abstract: axicabtagene ciloleucel |
| PMID 36646322 | Quality-Adjusted Time without Symptoms or Toxicity: Analysis of Axicabtagene Ciloleucel versus Standard of Care in Patients with Relapsed/Refractory Large B Cell Lymphoma. | Transplantation and cellular therapy | 2023 | name in title: axicabtagene ciloleucel |
| PMID 36821768 | Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. | Blood | 2023 | cited by trial NCT02348216 |
| PMID 36950962 | Myelodysplastic syndrome following chimeric antigen receptor T-cell therapy treated with allogenic stem cell transplantation. | Immunotherapy | 2023 | name in abstract: axicabtagene ciloleucel |
| PMID 36964939 | Response rates of extra-nodal diffuse large B cell lymphoma to anti-CD19-CAR T cells: A real word retrospective multicenter study. | European journal of haematology | 2023 | name in abstract: axicabtagene ciloleucel |
| PMID 36999993 | Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2023 | name in title: axicabtagene ciloleucel |
| PMID 37126659 | Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma. | Blood advances | 2023 | name in title: axicabtagene ciloleucel |
| PMID 37272527 | Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. | The New England journal of medicine | 2023 | name in title: axicabtagene ciloleucel |
| PMID 37399456 | A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell-associated neurotoxicity syndrome. | Blood advances | 2023 | name in abstract: axicabtagene ciloleucel |
| PMID 37400640 | CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. | Nature medicine | 2023 | name in abstract: axicabtagene ciloleucel |
| PMID 37522731 | Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma. | Blood advances | 2023 | name in title: axi-cel |
| PMID 37527011 | Axicabtagene Ciloleucel in Combination with the 4-1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2023 | name in title: axicabtagene ciloleucel |
| PMID 37625977 | Accelerated cortical atrophy and hypometabolism following axicabtagene ciloleucel treatment: A case report. | Revue neurologique | 2023 | name in title: axicabtagene ciloleucel |
| PMID 37659694 | Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study. | Transplantation and cellular therapy | 2023 | name in abstract: axi-cel |
| PMID 37710005 | Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. | Nature medicine | 2023 | cited by trial NCT04531046 |
| PMID 37841271 | Case Report: Invasive fungal infection after anti-CD19 CAR-T cell therapy. Implication for antifungal prophylaxis. | Frontiers in immunology | 2023 | name in abstract: axicabtagene ciloleucel |
| PMID 37842456 | Anti-CD19 Chimeric Antigen Receptor T Cell Therapy With Tisagenlecleucel for Secondary Central Nervous System Lymphoma: A Case Series. | Cureus | 2023 | name in abstract: axicabtagene ciloleucel |
| PMID 37946255 | Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study. | Journal of hematology & oncology | 2023 | name in abstract: axi-cel |
| PMID 38022532 | Targeting regulatory T cells by E7777 enhances CD8 T-cell-mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models. | Frontiers in immunology | 2023 | cited by trial NCT04855253 |
| PMID 34233446 | Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort study. | Haematologica | 2022 | name in abstract: axicabtagene ciloleucel |
| PMID 34259446 | Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study. | Critical care medicine | 2022 | name in abstract: axicabtagene ciloleucel |
| PMID 34599413 | Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma. | International journal of clinical oncology | 2022 | name in title: axicabtagene ciloleucel |
| PMID 34727319 | Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma in Chinese patients. | Frontiers of medicine | 2022 | name in abstract: axicabtagene ciloleucel |
| PMID 34891224 | Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. | The New England journal of medicine | 2022 | name in title: axicabtagene ciloleucel |
| PMID 34895487 | Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. | The Lancet. Oncology | 2022 | name in title: axicabtagene ciloleucel |
| PMID 34922648 | 2021 ASH annual meeting. | The Lancet. Haematology | 2022 | cited by trial NCT03391466 |
| PMID 34950390 | Recurrent Status Epilepticus in the Setting of Chimeric Antigen Receptor (CAR)-T Cell Therapy. | The Neurohospitalist | 2022 | name in abstract: axicabtagene ciloleucel |
| PMID 35114155 | The role of conferences in tackling inequalities. | The Lancet. Haematology | 2022 | cited by trial NCT03391466 |
| PMID 35314842 | Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. | Nature medicine | 2022 | name in title: axicabtagene ciloleucel |
| PMID 35403693 | FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma. | The oncologist | 2022 | name in title: axicabtagene ciloleucel |
| PMID 35404315 | Axicabtagene Ciloleucel in Patients Ineligible for ZUMA-1 Because of CNS Involvement and/or HIV: A Multicenter Experience. | Journal of immunotherapy (Hagerstown, Md. : 1997) | 2022 | name in title: axicabtagene ciloleucel |
| PMID 35839452 | Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. | Blood | 2022 | name in title: axicabtagene ciloleucel |
| PMID 35850429 | Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas. | Transplantation and cellular therapy | 2022 | name in title: axicabtagene ciloleucel |
| PMID 36116729 | Late haemophagocytic lymphohistiocytosis in a patient treated with Axicabtagene ciloleucel. | Transplant immunology | 2022 | name in title: axicabtagene ciloleucel |
| PMID 36648879 | It Is in the Eye of the Beholder: Ocular Ultrasound Enhanced Monitoring of Neurotoxicity after CAR-T Cell Therapy. | Hematology reports | 2022 | name in abstract: axicabtagene ciloleucel |
| PMID 33288485 | Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. | Clinical lymphoma, myeloma & leukemia | 2021 | cited by trial NCT03391466 |
| PMID 33334730 | A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy. | Cancer discovery | 2021 | cited by trial NCT02348216 |
| PMID 33385585 | A Real-Time Quantitative PCR Targeting the Viral Vector for the Monitoring of Patients Treated with Axicabtagene Ciloleucel. | The Journal of molecular diagnostics : JMD | 2021 | name in title: axicabtagene ciloleucel |
| PMID 33509115 | Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy - a case report. | BMC infectious diseases | 2021 | name in abstract: axicabtagene ciloleucel |
| PMID 33608749 | Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice. | European journal of clinical pharmacology | 2021 | name in abstract: axicabtagene ciloleucel |
| PMID 33623881 | Human Herpesvirus 6 Encephalitis Following Axicabtagene Ciloleucel Treatment for Refractory Diffuse Large B Cell Lymphoma. | HemaSphere | 2021 | name in title: axicabtagene ciloleucel |
| PMID 33641257 | Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucel. | Cancer medicine | 2021 | name in title: axicabtagene ciloleucel |
| PMID 34041526 | CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. | Blood | 2021 | name in title: axicabtagene ciloleucel |
| PMID 34133196 | Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2021 | name in title: axicabtagene ciloleucel |
| PMID 34166502 | CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. | Blood | 2021 | name in abstract: axicabtagene ciloleucel |
| PMID 34265479 | Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies. | Transplantation and cellular therapy | 2021 | name in abstract: axicabtagene ciloleucel |
| PMID 34296427 | Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. | British journal of haematology | 2021 | cited by trial NCT02348216 |
| PMID 34310745 | Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials. | American journal of hematology | 2021 | cited by trial NCT02348216 |
| PMID 34336692 | Successful Chimeric Antigen Receptor (CAR) T-Cell Treatment in Aggressive Lymphoma Despite Coronavirus Disease 2019 (CoVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication - Case Report. | Frontiers in oncology | 2021 | name in abstract: axicabtagene ciloleucel |
| PMID 34493319 | Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma. | Journal of hematology & oncology | 2021 | cited by trial NCT02348216 |
| PMID 34496024 | Fatal late-onset CAR T-cell-mediated encephalitis after axicabtagene-ciloleucel in a patient with large B-cell lymphoma. | Blood advances | 2021 | name in title: axicabtagene ciloleucel |
| PMID 34515338 | Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. | The Cochrane database of systematic reviews | 2021 | cited by trial NCT02348216 |
| PMID 34590303 | Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. | British journal of haematology | 2021 | name in title: axicabtagene ciloleucel |
| PMID 34697175 | Pembrolizumab-induced Remission After Failure of Axicabtagene Ciloleucel: Case Report and Literature Review. | In vivo (Athens, Greece) | 2021 | name in title: axicabtagene ciloleucel |
| PMID 35845220 | Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy following anti-CD19 CAR-T therapy: a case report. | EJHaem | 2021 | name in abstract: axicabtagene ciloleucel |
| PMID 31725923 | Axicabtagene ciloleucel for CD19+ plasmablastic lymphoma. | American journal of hematology | 2020 | name in title: axicabtagene ciloleucel |
| PMID 31959992 | Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. | Nature medicine | 2020 | name in abstract: axicabtagene ciloleucel |
| PMID 31973908 | Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma. | American journal of kidney diseases : the official journal of the National Kidney Foundation | 2020 | name in abstract: axicabtagene ciloleucel |
| PMID 32001800 | Fatal Mycobacterium abscessus in a recipient of axicabtagene ciloleucel CAR-T: beware of T cells. | Bone marrow transplantation | 2020 | name in title: axicabtagene ciloleucel |
| PMID 32181801 | Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. | Blood | 2020 | name in title: axicabtagene ciloleucel |
| PMID 32242358 | KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. | The New England journal of medicine | 2020 | cited by trial NCT02601313 |
| PMID 32271899 | Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. | Blood advances | 2020 | name in abstract: axicabtagene ciloleucel |
| PMID 32667831 | Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2020 | name in title: axicabtagene ciloleucel |
| PMID 32669372 | Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2020 | name in title: axicabtagene ciloleucel |
| PMID 32744738 | Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center. | American journal of hematology | 2020 | name in abstract: axicabtagene ciloleucel |
| PMID 32777012 | Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy. | JAMA neurology | 2020 | name in abstract: axicabtagene ciloleucel |
| PMID 32998963 | Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2020 | cited by trial NCT04071366 |
| PMID 33020644 | Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. | Nature medicine | 2020 | name in abstract: axicabtagene ciloleucel |
| PMID 33021872 | Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2020 | name in abstract: axicabtagene ciloleucel |
| PMID 33035333 | Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. | Blood advances | 2020 | cited by trial NCT02348216 |
| PMID 33067318 | Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2. | Journal for immunotherapy of cancer | 2020 | cited by trial NCT02601313 |
| PMID 30413526 | FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2019 | name in title: axicabtagene ciloleucel |
| PMID 30518502 | Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. | The Lancet. Oncology | 2019 | cited by trial NCT02348216 |
| PMID 31211433 | Obinutuzumab as bridging therapy for successful manufacturing of axicabtagene ciloleucel for transformed follicular lymphoma with circulating cells. | American journal of hematology | 2019 | name in title: axicabtagene ciloleucel |
| PMID 31685159 | Axicabtagene Ciloleucel Chimeric Antigen Receptor T Cell Therapy in Lymphoma With Secondary Central Nervous System Involvement. | Mayo Clinic proceedings | 2019 | name in title: axicabtagene ciloleucel |
| PMID 28129122 | Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. | Molecular therapy : the journal of the American Society of Gene Therapy | 2017 | name in title: KTE-C19 |
| PMID 29226797 | Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. | The New England journal of medicine | 2017 | cited by trial NCT02348216 |
Other papers
Preclinical studies, reviews and other papers that name it, newest 100 shown.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 39410883 | Neurotoxicity associated with chimeric antigen receptor T-cell therapy: a real-world study leveraging the FDA Adverse Event Reporting System. | Expert opinion on drug safety | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 40373976 | Health and Economic Impact of Vein-to-Vein Time in CAR T-Cell Therapy in the Second-Line Treatment of Relapsed/Refractory Large B-Cell Lymphoma: A US Cost-Effectiveness Analysis. | Transplantation and cellular therapy | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 40637750 | Safety and efficacy of bridging radiation therapy prior to CD19 CAR T for non-Hodgkin lymphoma: a systematic review and meta-analysis. | Haematologica | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 40953732 | Impact of Granulocyte Colony Stimulating Factor Use Following CD-19 Chimeric Antigen Receptor T-Cell Therapy. | Transplantation and cellular therapy | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 40968610 | Effectiveness of CAR-T Cell Therapies for Relapsed/Refractory Follicular Lymphoma: An External Control Arm Study. | Cancer research and treatment | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41138816 | Who Is Eligible for Chimeric Antigen Receptor T Cell Therapy? Expert Perspectives on Overcoming Referral Barriers. | Transplantation and cellular therapy | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41143460 | A Pharmacologic Model Predicts that Tumor Debulking Improves CAR T-cell Efficacy in Large B-cell Lymphoma. | Blood cancer discovery | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41183747 | Comparative Analysis of Lymphodepletion Regimens in CART-19 Treatment for Relapsed/Refractory Diffuse Large B Cell Lymphoma. | Transplantation and cellular therapy | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41247641 | Low reticulocyte count at infusion is a risk factor for high-grade cytokine release syndrome in chimeric antigen receptor T cell therapy. | International journal of hematology | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41263639 | Beyond Expansion: Tumor Debulking as Key to Improving CAR T-Cell Potential in Lymphoma. | Blood cancer discovery | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41345759 | Comparative Economic Evaluations of CAR-T Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Systematic Review. | PharmacoEconomics | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41355413 | Short-term costs associated with outpatient use of axicabtagene ciloleucel in second-line and above relapsed/refractory large B-cell lymphoma based on the zuma-24 clinical trial. | Leukemia & lymphoma | 2026 | name in title: axicabtagene ciloleucel |
| PMID 41391508 | Immune Effector Cell-Associated HLH-Like Syndrome (IEC-HS) in CAR-T and TCE-Treated Myeloma and B-Cell Malignancies: Insights from a Pharmacovigilance Study. | Transplantation and cellular therapy | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41396346 | Cost-Effectiveness of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Blood Cancers: An Updated Systematic Review. | PharmacoEconomics - open | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41448297 | Chimeric antigen receptor T-cell therapy and immune effector cell-associated neurotoxicity syndrome: A meta-analysis. | Critical reviews in oncology/hematology | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41467613 | Axicabtagene ciloleucel demonstrates superior outcomes over historically available treatments in relapsed/refractory follicular lymphoma: 5-year comparative analysis between ZUMA-5 and SCHOLAR-5. | Leukemia & lymphoma | 2026 | name in title: axicabtagene ciloleucel |
| PMID 41483380 | Safety and effectiveness of lisocabtagene maraleucel following PD-1 blockade in relapsed or refractory PMBCL. | International journal of hematology | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41492445 | Efficacy and safety of chimeric antigen receptor T-cell therapy in relapsed/refractory large B-cell lymphoma: a systematic review and meta-analysis. | Therapeutic advances in hematology | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41525947 | Impact of Complete Response on Long-Term Survival in Patients with Relapsed or Refractory Large B-cell Lymphoma: A Center for International Blood and Marrow Transplant Research Prospective Study and Systematic Literature Review/Meta-Analysis. | Transplantation and cellular therapy | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41529329 | Impact of CD5 expression on outcomes for chimeric antigen receptor-T cell therapy in relapsed and refractory diffuse large B-cell lymphoma. | Cytotherapy | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41546434 | Brain Microstructural Damage as Potential Biomarker of Immune Cell-Associated Neurotoxicity Syndrome. | Journal of neuroimaging : official journal of the American Society of Neuroimaging | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41555654 | Single-centre analysis of prophylactic dexamethasone on the incidence and severity of cytokine release syndrome and immune effector cell-associated neurotoxicity in patients receiving axicabtagene ciloleucel. | British journal of haematology | 2026 | name in title: axicabtagene ciloleucel |
| PMID 41582602 | Microbiome-Based Modeling of CAR-T Therapy Response in Lymphoma: Insights From Shotgun Metagenomics Sequencing. | European journal of haematology | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41596518 | Apheresis CD8+CCR7+CD45RA- T-Cells as a Novel Biomarker Associated with CAR T-Cell Kinetics and Clinical Outcome. | International journal of molecular sciences | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41676895 | ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot study. | Haematologica | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41698482 | Hypogammaglobulinemia at Leukapheresis Predicts Delayed Humoral Immune Reconstitution and Increased Risk of Infections After CD19 CAR-T for B-Cell Lymphoma. | Transplantation and cellular therapy | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41743266 | Outcomes of second-line axicabtagene ciloleucel for large B-cell lymphoma in the UK. | HemaSphere | 2026 | name in title: axicabtagene ciloleucel |
| PMID 41744849 | Real-World Outcomes of Axicabtagene Ciloleucel for Treatment of Relapsed or Refractory Large B-Cell Lymphoma in Canada. | Current oncology (Toronto, Ont.) | 2026 | name in title: axicabtagene ciloleucel |
| PMID 41748023 | Association Between Patient-Reported Outcomes Prior to Chimeric Antigen Receptor (CAR) T-Cell Therapy and Clinical Outcomes. | Transplantation and cellular therapy | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41762956 | Low reticulocyte count at infusion is a risk factor for ICANS in CAR-T cell therapy. | Cytotherapy | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41774434 | A new era for transplant-ineligible R/R LBCL patients: what's changing? | Leukemia & lymphoma | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41777657 | Advancing access to CAR T-cell therapy: insights and real-world experience from a community oncology practice. | Frontiers in oncology | 2026 | name in abstract: axi-cel |
| PMID 41855506 | Early steroid and anakinra use to manage axicabtagene ciloleucel toxicity reduces the total duration of CRS and ICANS. | Blood advances | 2026 | name in title: axicabtagene ciloleucel |
| PMID 41857785 | A global multidimensional analysis of the chimeric antigen receptor T-cell therapy clinical trial landscape and development trends. | Biomarker research | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41866225 | Spinal cord disease following CAR T-cell therapy with axicabtagene ciloleucel in a patient with high-grade B-cell lymphoma. | Leukemia & lymphoma | 2026 | name in title: axicabtagene ciloleucel |
| PMID 41867486 | Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomas. | Blood neoplasia | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41891043 | Cell-free RNA Signatures Derived from the Tumor Microenvironment Predict Outcomes of CAR-T Therapy in Large B Cell Lymphoma. | medRxiv : the preprint server for health sciences | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41894687 | Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma. | Blood advances | 2026 | name in title: axi-cel |
| PMID 41923554 | Circulating CAR T-Cells After Treatment With Axicabtagene Ciloleucel in Patients With Relapsed/Refractory Aggressive B-Cell Lymphomas and Its Association to Treatment Outcome. | European journal of haematology | 2026 | name in title: axicabtagene ciloleucel |
| PMID 41935576 | Neurotoxicity in Older Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy: A Multicenter Study. | Transplantation and cellular therapy | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41964291 | Impaired hematopoiesis affects apheresis and CAR T-cell product composition and treatment response. | Transfusion | 2026 | name in abstract: axi-cel |
| PMID 41968224 | Real-world outcomes of chimeric antigen receptor T-cell therapy with pembrolizumab as holding and/or bridging therapy in relapsed/refractory primary mediastinal large B-cell lymphoma. | International journal of clinical oncology | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 41979680 | Distinct cellular signatures in aplastic and intermittent phenotypes of immune effector cell-associated hematotoxicity. | Annals of hematology | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42018609 | Drivers of temporal improvement in CAR T-cell therapy for large B-cell lymphoma: a Japanese nationwide registry analysis. | Blood advances | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42028025 | Longitudinal ctDNA tracking by low-pass whole-genome sequencing predicts CAR-T outcomes in B-cell lymphomas. | iScience | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42038359 | Clinical implementation of a one-step no-wash flow cytometry method allows for real-time monitoring of patients treated with autologous CAR-T cells. | Frontiers in oncology | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42052989 | Unraveling the care pathway for CAR T-cell therapy in large B-cell lymphoma: insights from a nationwide study in France (2018-2023). | Leukemia & lymphoma | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42086512 | Hemophagocytic Lymphohistiocytosis After CAR T-Cell Therapy: A Systematic Review and Meta-Analysis. | American journal of hematology | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42099680 | Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group. | HemaSphere | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42101810 | Economic Evaluation of Axicabtagene Ciloleucel as a Second-Line Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in South Korea: A Cost-Utility Analysis Based on the ZUMA-7 Trial. | Clinical drug investigation | 2026 | name in title: axicabtagene ciloleucel |
| PMID 42112708 | Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy. | Cancer immunology research | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42118449 | T-cell fitness, metabolic tumor volume, and serum LDH levels are associated with response to axicabtagene ciloleucel. | International journal of hematology | 2026 | name in title: axicabtagene ciloleucel |
| PMID 42119568 | Real-World Experience With a ZUMA-1 Cohort 4 Adopted Approach to CRS and ICANS in CAR-T Recipients. | European journal of haematology | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42137294 | Comparative pharmacokinetic derivations for axicabtagene ciloleucel and brexucabtagene autoleucel in the treatment of B cell malignancies. | Molecular therapy. Advances | 2026 | name in title: axicabtagene ciloleucel |
| PMID 42138782 | Indirect Treatment Comparisons of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in Third-Line or Later Relapsed or Refractory Follicular Lymphoma. | Advances in therapy | 2026 | name in title: axicabtagene ciloleucel |
| PMID 42140929 | Naïve CD4+ T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy. | Nature communications | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42157590 | Persistent CAR-T signal in delayed immune effector cell-associated enterocolitis following axicabtagene ciloleucel. | Leukemia & lymphoma | 2026 | name in title: axicabtagene ciloleucel |
| PMID 42169662 | Hypophosphatemia as a Marker for Immune Effector Cell-Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor T Cell Recipients. | Hematology/oncology and stem cell therapy | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42173255 | Prolonged Cytokine Release Syndrome is Associated with Hypofibrinogenemia after CD19-Directed CAR T-Cell Therapy in Adult Patients with Relapsed/Refractory Lymphoma. | Transplantation and cellular therapy | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42251173 | Impact of fludarabine dosage on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the EBMT. | Bone marrow transplantation | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42265975 | Beyond Chemoimmunotherapy: Emerging Cellular and Targeted Therapies in Transformed Follicular Lymphoma: A Scoping Review. | Cancer control : journal of the Moffitt Cancer Center | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42269079 | Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma. | Blood advances | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42279369 | Prophylactic Anakinra to Prevent Neurotoxicity After CAR T-Cell Therapy in Aggressive B-Cell Lymphomas: A Single-Center Real-World Experience. | Cancers | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42305450 | Comparative efficacy and safety of systemic therapies in transplant-eligible and ineligible relapsed/refractory large B-cell lymphoma: a Bayesian network meta-analysis. | Translational cancer research | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42329247 | Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma. | Oncology (Williston Park, N.Y.) | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42341926 | Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma. | Transplantation and cellular therapy | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42359427 | Durability Benchmarking of Contemporary Second-Line and Later Therapies for Relapsed or Refractory Follicular Lymphoma Using Reconstructed Individual Patient Data From Published Kaplan-Meier Curves. | Cureus | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42381271 | Immune effector cell-associated hematotoxicity following CAR-T cell therapies: insights from a large national database. | Japanese journal of clinical oncology | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42416925 | Identification of an optimal absolute lymphocyte count at leukapheresis in patients with lymphoma treated with CART. | Blood immunology & cellular therapy | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42428526 | Comparative efficacy and toxicity of Axicabtagene Ciloleucel versus Tisagenlecleucel in European patients with large B-cell lymphoma: a systematic review and meta-analysis. | PeerJ | 2026 | name in title: axicabtagene ciloleucel |
| PMID 42453534 | Risk of thrombosis and bleeding following CAR T-cell therapy: Insights from the Dutch "Follow that CAR!" registry. | HemaSphere | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42471153 | Transfusion support after CAR-T cell therapy: Real-world patterns across commercial products and disease groups. | Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42482164 | Model-Based Analysis with Mechanistic Insights to CAR-T-Cell Therapy Kinetics: Case Study with Axicabtagene Ciloleucel and Brexucabtagene Autoleucel. | Clinical pharmacology and therapeutics | 2026 | name in title: axicabtagene ciloleucel |
| PMID 42489073 | TAFRO-like syndrome associated with long-term CAR-T cell persistence after axicabtagene ciloleucel therapy. | Haematologica | 2026 | name in title: axicabtagene ciloleucel |
| PMID 42497245 | Genomic correlates of clinical CAR T cell activity. | Science immunology | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42507490 | Systematic literature review of clinical outcomes, health-related quality of life, and healthcare costs and resource use in relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel. | Leukemia & lymphoma | 2026 | name in title: axicabtagene ciloleucel |
| PMID 42527721 | Follicular Lymphoma: Novel Therapies and Strategies for Optimal Therapeutic Sequencing. | Current oncology reports | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42537846 | Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel Chimeric Antigen Receptor T-Cell Therapy: Center for International Blood and Marrow Transplant Research Data. | Transplantation and cellular therapy | 2026 | name in title: axicabtagene ciloleucel |
| PMID 42556536 | Impact of Prior Bendamustine Exposure on Chimeric Antigen Receptor T-Cell Therapy Outcomes in Follicular Lymphoma. | Transplantation and cellular therapy | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42567965 | Effectiveness of anti-CD19 CAR T-cell therapy for high-grade B-cell lymphoma in Japan: a single-institution analysis. | International journal of clinical oncology | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42568509 | CD19 CAR-T cell therapy in large B-cell lymphoma: clinical evidence, resistance, toxicity, and precision strategies. | Frontiers in immunology | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42596901 | Impact on health outcomes of treating all eligible large B-cell lymphoma patients with axicabtagene ciloleucel in Portugal - A modeling approach. | Journal of medical economics | 2026 | name in title: axicabtagene ciloleucel |
| PMID 42600565 | Shortened axi-cel manufacturing drives rapid in vivo expansion and shifts the acute toxicity profile in R/R LBCL. | Blood advances | 2026 | name in title: axi-cel |
| PMID 42610412 | Improved progression free survival after axicabtagene ciloleucel compared to tisagenlecleucel, in patients aged >70 years with large B-cell lymphoma. | Haematologica | 2026 | name in title: axicabtagene ciloleucel |
| PMID 42625595 | Post-CAR T-cell thyroid dysfunction: destructive thyroiditis identified through thyroid function monitoring in a single-center cohort. | Frontiers in oncology | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42640449 | Persistent parkinsonism with dopaminergic denervation following axicabtagene ciloleucel therapy for diffuse large B cell lymphoma: a case report. | International journal of hematology | 2026 | name in title: axicabtagene ciloleucel |
| PMID 42645791 | Factors Associated with Increased Healthcare Utilization Within 30 and 90 Days Post-Discharge of CAR-T Cell Therapy in Patients with R/R LBCL. | Hematology reports | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42648741 | Implementation and use of risk minimization control tools in the EU: A multistakeholder survey. | British journal of clinical pharmacology | 2026 | name in abstract: Yescarta |
| PMID 42660975 | Tisa-cel and axi-cel CAR structure influences the development of resistance to CD19-CAR-T therapy. | Leukemia | 2026 | name in title: axi-cel |
| PMID 42663433 | InflaMix Predicts Severe CRS, ICU Admission, and Progression-Free Survival After CAR-T Therapy in LBCL. | European journal of haematology | 2026 | name in abstract: axi-cel |
| PMID 42671910 | Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma. | Blood cancer discovery | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42686451 | In Search of Long-Term Disease Control: CAR T-Cell Therapy With Axicabtagene Ciloleucel or Allogeneic Hematopoietic Cell Transplantation Against Relapsed/Refractory Large B-Cell Lymphoma. | Clinical lymphoma, myeloma & leukemia | 2026 | name in title: axicabtagene ciloleucel |
| PMID 42704001 | Dynamic risk stratification using early CAR-T expansion in R/R LBCL treated with axicabtagene ciloleucel. | British journal of haematology | 2026 | name in title: axicabtagene ciloleucel |
| PMID 42709238 | Age as a moderator of neurocognitive performance in patients with large B-cell lymphoma treated with axicabtagene ciloleucel. | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer | 2026 | name in title: axicabtagene ciloleucel |
| PMID 42726020 | Reusable Pipeline for Converting Real-World Lymphoma Registry Data to CDISC Standards: Implementation and Validation Using Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence. | JCO clinical cancer informatics | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42774885 | Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis. | HemaSphere | 2026 | name in title: axicabtagene ciloleucel |
| PMID 42777835 | Host immune biomarkers associated with infection risk after CAR T-cell therapy. | The Journal of infection | 2026 | name in abstract: axicabtagene ciloleucel |
| PMID 42800585 | Real-World Comparison of Axicabtagene Ciloleucel and Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: A Target Trial Emulation. | Transplantation and cellular therapy | 2026 | name in title: axicabtagene ciloleucel |
| PMID 42801949 | Prophylaxis with Dexamethasone or Anakinra in Patients with High-Risk Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel. | Transplantation and cellular therapy | 2026 | name in title: axicabtagene ciloleucel |
| PMID 42807827 | Integrating new and "old" cellular therapies in the evolving landscape of relapsed or refractory large B-cell lymphoma. | Frontiers in oncology | 2026 | name in abstract: axi-cel |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| K08CA267307 | Determinants of Resistance to Engineered T-cell Therapies Targeting CD19 in Lymphoma | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE | SWORDER, BRIAN | 2023–2026 | name in abstract: axicabtagene ciloleucel |
| P30CA016520 | Pediatric Oncology Program | UNIVERSITY OF PENNSYLVANIA | GRUPP, STEPHAN A. | 2021–2026 | name in abstract: axicabtagene ciloleucel |
| P30CA016672 | Stem Cell Biology & Cellular Therapy Program | UNIVERSITY OF TX MD ANDERSON CAN CTR | SHPALL, ELIZABETH J | 2019–2026 | name in abstract: axicabtagene ciloleucel |
| R01CA309280 | Engineering CD19 mimotopes for enhancing and repurposing CD19-CAR T against hematological malignancies and solid tumors | CHILDREN'S HOSP OF PHILADELPHIA | MA, LEYUAN | 2026–2026 | name in abstract: Yescarta |
| R37CA250661 | Harnessing the thymus for long-term tumor control with hematopoietic stem cell-derived naive CAR T cells | HACKENSACK UNIVERSITY MEDICAL CENTER | ZAKRZEWSKI, JOHANNES | 2022–2026 | name in abstract: Yescarta |
| UG1HL108987 | Blood and Marrow Transplant Clinical Trials Network (BMT CTN) - Core Clinical Centers - UG1 | H. LEE MOFFITT CANCER CTR & RES INST | PIDALA, JOSEPH A | 2024–2026 | name in abstract: axicabtagene ciloleucel |
| UG1HL109137 | Phase III, Multicenter, Randomized, Double-Blind Study of Duvelisib as Cytokine Release Syndrome Prophylaxis in Patients with Large Cell or Mantle Cell Lymphoma Undergoing CAR T-Cell Therapies | WASHINGTON UNIVERSITY | PUSIC, ISKRA | 2024–2026 | name in abstract: axicabtagene ciloleucel |
| R01CA252940 | Efficacy and immune effects of anakinra prophylaxis for neurologic toxicity and cytokine release syndrome in patients with lymphoma receiving axicabtagene ciloleucel | MASSACHUSETTS GENERAL HOSPITAL | MAUS, MARCELA VALDERRAMA | 2020–2024 | name in title: axicabtagene ciloleucel |
| R21CA259694 | Targeting Myeloid Cells to Mitigate Immune Effector Cell-Associated Neurotoxicity Syndrome in Large B-cell Lymphoma | UNIVERSITY OF TX MD ANDERSON CAN CTR | STRATI, PAOLO | 2021–2021 | name in abstract: axi-cel |
Notes
Gammaretroviral anti-CD19 (FMC63) CD28 CAR from NCI Surgery Branch, licensed to Kite. Same CAR as brexucabtagene autoleucel; different manufacturing.
How to cite
axicabtagene ciloleucel (AXP000014.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000014.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.